Why might a patient experience weight gain while being treated with tirzepatide?

Weight Gain on Tirzepatide: Understanding the Paradox

Weight gain while taking tirzepatide is extremely uncommon and typically occurs only after discontinuation of the medication, not during active treatment. Tirzepatide is one of the most potent weight-loss medications available, with mean weight reductions of 20.9% after 36 weeks and 25.3% at 88 weeks of continuous treatment 1.

Why Weight Gain Occurs: Medication Withdrawal

The primary mechanism for weight gain in tirzepatide-treated patients is discontinuation of therapy:

• Withdrawal leads to substantial weight regain: When tirzepatide is stopped after achieving weight loss, patients regain a mean of 14.0% of their body weight within 52 weeks, compared to an additional 5.5% weight loss in those who continue treatment 1

• Most patients regain significant weight: Among those who discontinued tirzepatide after initial weight loss, 83.4% regained more than 20% of their lost weight within one year 1

• Cardiometabolic parameters deteriorate with regain: Weight regain of 25% or more is associated with reversal of metabolic improvements, including increased waist circumference (5.4-14.7 cm), elevated systolic blood pressure (7.3-10.4 mm Hg), and worsening HbA1c (0.15-0.35%) 2

Weight Plateau vs. Weight Gain During Treatment

During active treatment, patients reach a weight plateau but do not typically gain weight:

• Plateau timing varies by baseline BMI: Median time to weight plateau ranges from 24.3 weeks (overweight) to 36.1 weeks (class II-III obesity) 3

• 90% reach plateau by week 72: Most adherent patients (87.6-90.2%) achieve a stable weight plateau rather than weight regain during continued treatment 3

• Higher doses delay plateau: Patients on 10-15 mg doses reach weight plateau later than those on 5 mg, indicating more sustained weight loss 3

Concomitant Medications That Promote Weight Gain

Weight gain may occur if tirzepatide is combined with weight-promoting diabetes medications:

• Insulin causes weight gain: When tirzepatide is added to existing insulin therapy without dose reduction, the weight-promoting effects of insulin may counteract tirzepatide's benefits 4

• Sulfonylureas promote weight gain: These medications should be used judiciously at the lowest possible dose when combined with tirzepatide 4

• Thiazolidinediones increase weight: These agents promote weight gain and should be avoided or minimized in patients with obesity 4

Clinical Pitfalls to Avoid

Common scenarios that may lead to perceived weight gain:

• Premature discontinuation: Stopping tirzepatide due to mild gastrointestinal side effects (nausea 17-31%, diarrhea 12-23%) leads to rapid weight regain 5

• Inadequate dose titration: Remaining on the 2.5 mg starting dose instead of escalating to maintenance doses (5-15 mg) results in suboptimal weight loss 5

• Failure to adjust concomitant medications: Not reducing insulin or sulfonylurea doses when initiating tirzepatide may blunt weight loss effects 6

• Insurance-driven discontinuation: Loss of medication access due to formulary changes or cost barriers leads to weight regain 7

Management Algorithm

If a patient reports weight gain on tirzepatide:

1. Verify medication adherence: Confirm the patient is actually taking tirzepatide weekly and has not discontinued therapy

2. Review concomitant medications: Identify and reduce doses of insulin, sulfonylureas, or thiazolidinediones 4

3. Assess current dose: Ensure the patient has been appropriately titrated to maintenance doses (5-15 mg) rather than remaining on the 2.5 mg starting dose 5

4. Evaluate timing: Determine if weight gain occurred during active treatment (unusual) or after discontinuation (expected) 1

5. Consider weight plateau: Distinguish between reaching a stable weight plateau (normal at 24-36 weeks) versus actual weight regain 3

The key clinical message: Weight gain during active tirzepatide treatment is atypical and warrants investigation for medication non-adherence, inadequate dosing, or counteracting medications. True weight gain most commonly occurs after discontinuation, emphasizing the need for continued long-term treatment 2, 1.